Description
Type 2 Diabetes: To improve glycemic control and reduce the risk of major cardiovascular events like heart attack or stroke.
Weight Management: For adults with obesity (BMI≥30) or overweight (BMI≥27) with at least one weight-related condition.
Cardiovascular Health: Specifically approved to reduce the risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease and either diabetes or obesity.
Chronic Kidney Disease: Recently used to lower the risk of worsening kidney disease and related deaths in patients with type 2 diabetes.
Liver Disease (MASH): Investigated for metabolic dysfunction-associated steatohepatitis (formerly NASH) with moderate to advanced scarring
Reviews
There are no reviews yet.